- JP-listed companies
- Cuorips Inc.
- Income statement
Cuorips Inc. (4894) Income statement
Market cap
¥35.3B
P/E ratio
-25.8x
Qualips develops regenerative medicine treatments using human iPS cells, specializing in cardiac muscle cell sheets for severe heart failure patients.
| 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | - | - | - | 0 | 14 | 38 | 23 | 175 | 212 |
| Revenue growth (%) | - | - | - | - | |||||
| Cost of revenue | - | - | - | 0 | 3 | 17 | 13 | 7 | 82 |
| Gross profit | - | - | - | 0 | 11 | 21 | 10 | 168 | 130 |
| Gross margin (%) | - | - | - | ||||||
| Operating margin (%) | - | - | - | ||||||
| Operating expenses | - | - | - | 282 | 384 | 471 | 598 | 759 | 1,212 |
| Operating income | - | - | - | -282 | -373 | -450 | -588 | -590 | -1,081 |
| Income before tax | -60 | -144 | -177 | -296 | -373 | -450 | -628 | -642 | -1,028 |
| Pretax margin (%) | - | - | - | -134,475 | -2,682 | -1,176.7 | -2,718.1 | -366.4 | -484.9 |
| Provision for income taxes | - | - | - | 12 | 2 | 2 | 2 | 3 | 4 |
| Effective tax rate (%) | - | - | - | ||||||
| Net income | -27 | -128 | -180 | -308 | -375 | -452 | -632 | -644 | -771 |
| Earnings per share | -59.51 | -87.56 | -97.31 | -123.65 | -66.6 | -79.9 | -85.86 | -80.52 | -124.54 |
| Dividend per share | - | - | - | - | - | - | - | - | - |